170 related articles for article (PubMed ID: 30314949)
1. Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study.
Brighi N; Lamberti G; Maggio I; Manuzzi L; Ricci C; Casadei R; Santini D; Mosconi C; Lisotti A; Ambrosini V; Pantaleo MA; Campana D
Dig Liver Dis; 2019 May; 51(5):689-694. PubMed ID: 30314949
[TBL] [Abstract][Full Text] [Related]
2. Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study.
Brighi N; Panzuto F; Modica R; Gelsomino F; Albertelli M; Pusceddu S; Massironi S; Lamberti G; Rinzivillo M; Faggiano A; Spallanzani A; Ferone D; Prinzi N; Rossi RE; Annibale B; Colao AM; Campana D
Oncologist; 2020 Mar; 25(3):259-265. PubMed ID: 32162819
[TBL] [Abstract][Full Text] [Related]
3. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects.
Eriksson B; Renstrup J; Imam H; Oberg K
Ann Oncol; 1997 Oct; 8(10):1041-4. PubMed ID: 9402179
[TBL] [Abstract][Full Text] [Related]
4. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs.
Imam H; Eriksson B; Lukinius A; Janson ET; Lindgren PG; Wilander E; Oberg K
Acta Oncol; 1997; 36(6):607-14. PubMed ID: 9408151
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients.
Attanasio R; Mainolfi A; Grimaldi F; Cozzi R; Montini M; Carzaniga C; Grottoli S; Cortesi L; Albizzi M; Testa RM; Fatti L; De Giorgio D; Scaroni C; Cavagnini F; Loli P; Pagani G; Ghigo E
J Endocrinol Invest; 2008 Aug; 31(8):704-10. PubMed ID: 18852531
[TBL] [Abstract][Full Text] [Related]
6. Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly.
Turner HE; Lindsell DR; Vadivale A; Thillainayagam AV; Wass JA
Eur J Endocrinol; 1999 Dec; 141(6):590-4. PubMed ID: 10601961
[TBL] [Abstract][Full Text] [Related]
7. Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis.
Ryan P; McBride A; Ray D; Pulgar S; Ramirez RA; Elquza E; Favaro JP; Dranitsaris G
J Oncol Pharm Pract; 2019 Sep; 25(6):1425-1433. PubMed ID: 30924737
[TBL] [Abstract][Full Text] [Related]
8. Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis.
Rossi RE; Invernizzi P; Mazzaferro V; Massironi S
United European Gastroenterol J; 2020 Mar; 8(2):140-147. PubMed ID: 32213066
[TBL] [Abstract][Full Text] [Related]
9. Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors.
Machado-Alba JE; Machado-Duque ME; Gaviria-Mendoza A; Arsof-Saab IN; Castellanos-Moreno CA; Botero L; Triana L
J Endocrinol Invest; 2023 Jan; 46(1):27-35. PubMed ID: 35913681
[TBL] [Abstract][Full Text] [Related]
10. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.
Chan DL; Ferone D; Albertelli M; Pavlakis N; Segelov E; Singh S
Endocrine; 2017 Sep; 57(3):366-375. PubMed ID: 28726183
[TBL] [Abstract][Full Text] [Related]
11. Established clinical use of octreotide and lanreotide in oncology.
Oberg K
Chemotherapy; 2001; 47 Suppl 2():40-53. PubMed ID: 11275701
[TBL] [Abstract][Full Text] [Related]
12. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
13. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
Pokuri VK; Fong MK; Iyer R
Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
[TBL] [Abstract][Full Text] [Related]
14. Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor.
Lamberti G; Faggiano A; Brighi N; Tafuto S; Ibrahim T; Brizzi MP; Pusceddu S; Albertelli M; Massironi S; Panzuto F; Badalamenti G; Riccardi F; Butturini G; Gelsomino F; De Divitiis C; Modica R; Bongiovanni A; La Salvia A; Torchio M; Colao A; Ferone D; Campana D
J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31545377
[TBL] [Abstract][Full Text] [Related]
15. Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems.
Paisley AN; Roberts ME; Trainer PJ
Clin Endocrinol (Oxf); 2007 May; 66(5):723-6. PubMed ID: 17388793
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
Giusti M; Gussoni G; Cuttica CM; Giordano G
J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
[TBL] [Abstract][Full Text] [Related]
17. Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.
Bousquet C; Lasfargues C; Chalabi M; Billah SM; Susini C; Vezzosi D; Caron P; Pyronnet S
J Clin Endocrinol Metab; 2012 Mar; 97(3):727-37. PubMed ID: 22170729
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin Analogs and Tumor Localization Do Not Influence Vitamin D Concentration in Patients with Neuroendocrine Tumors.
Motylewska E; Gawronska J; Niedziela A; Melen-Mucha G; Lawnicka H; Komorowski J; Swietoslawski J; Stepien H
Nutr Cancer; 2016; 68(3):428-34. PubMed ID: 27028957
[TBL] [Abstract][Full Text] [Related]
19. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
Faiss S; Pape UF; Böhmig M; Dörffel Y; Mansmann U; Golder W; Riecken EO; Wiedenmann B;
J Clin Oncol; 2003 Jul; 21(14):2689-96. PubMed ID: 12860945
[TBL] [Abstract][Full Text] [Related]
20. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
